Epilepsy and COVID-19: patient management and optimization of antiepileptic therapy during pandemic

Rider, Flora; Лебедева, А. В.; Mkrtchyan, V. R.; Guekht, Alla

doi:10.17116/jnevro2020120101100

Cited by 8 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Especially for chronic diseases for which patients seem to follow a stable treatment that allows them to manage their condition (i.e., COPD, asthma, or other respiratory diseases), the complications of COVID-19 may raise new challenges and needs for therapy adjustments. Similar tasks may be raised for other cases of patients that receive chronic treatments, such as people with epilepsy or people with coagulation problems, to name some of a few [ 54 , 55 , 128 , 129 , 130 , 131 ]. Therefore, it is crucial that healthcare professionals, especially those in COVID-19 clinics, be as aware as possible regarding responsiveness and management of adverse drug events (ADEs), ADRS, and/or DDIs in order to ensure drug safety and avoid any misdiagnosis [ 94 , 95 , 123 , 124 , 125 , 132 , 133 ].…”

Section: Healthcare Personnel In Covid-19 Clinics: Identifying and Manage Ddis And Adrsmentioning

confidence: 99%

Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments

Spanakis

Patelarou

et al. 2021

IJERPH

View full text Add to dashboard Cite

Pandemic of coronavirus disease (COVID-19) is still pressing the healthcare systems worldwide. Thus far, the lack of available COVID-19-targeted treatments has led scientists to look through drug repositioning practices and exploitation of available scientific evidence for potential efficient drugs that may block biological pathways of SARS-CoV-2. Till today, several molecules have emerged as promising pharmacological agents, and more than a few medication protocols are applied during hospitalization. On the other hand, given the criticality of the disease, it is important for healthcare providers, especially those in COVID-19 clinics (i.e., nursing personnel and treating physicians), to recognize potential drug interactions that may lead to adverse drug reactions that may negatively impact the therapeutic outcome. In this review, focusing on patients with respiratory diseases (i.e., asthma or chronic obstructive pulmonary disease) that are treated also for COVID-19, we discuss possible drug interactions, their underlying pharmacological mechanisms, and possible clinical signs that healthcare providers in COVID-19 clinics may need to acknowledge as adverse drug reactions due to drug-drug interactions.

show abstract

Section: Healthcare Personnel In Covid-19 Clinics: Identifying and Manage Ddis And Adrsmentioning

confidence: 99%

Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments

Spanakis

Patelarou

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…The Russian vaccine Sputnik V, the world's fi rst registered coronavirus vaccine, is the most studied vaccine at the current time. Sputnik V is among the preferred vaccines after the Pfi zer/BioNTech vaccine and Russia is the most trusted vaccine manufacturer, along with the US [11]. Russian Federation Ministry of Health Order No.…”

mentioning

confidence: 99%

Effects of COVID-19 on the Course of Epilepsy

Одинцова

Nezdorovin

Нездоровина

2022

Neurosci Behav Physi

View full text Add to dashboard Cite

A comparative analysis of two case histories showing the effects of COVID-19 and immunization with the Sputnik V vaccine on the dynamics of epilepsy is presented. The study was part of the "Epilepsy and COVID-19" research initiative in a cohort of patients with epilepsy divided into two groups: those experiencing COVID-19 and those immunized with vaccine against COVID-19. We present here a comparative analysis of two case histories: recurrence of seizures in COVID-19 in a young (male) patient and good tolerance of vaccine in an older (female) patient with comorbid pathology after surgical treatment of drug-resistant epilepsy. Patient K (age 32 years, male) had generalized genetic (idiopathic) epilepsy with remission of seizures for three years. On the background of mild COVID-19 the patient experienced recurrence of generalized tonic-clonic seizures with deterioration of electroencephalographic indicators. Patient F (age 59 years, female) had focal drug-resistant epilepsy with remission of seizures for three years following surgical treatment, with comorbid endocrine pathology. No side effects were seen on immunization with Sputnik V vaccine and clinical-electroencephalographic remission persisted. The results showed good tolerance of Sputnik V vaccine, with persisting remission of seizures after neurosurgical treatment of drug-resistant epilepsy in the older patient with comorbid pathology and the potential for recurrence of seizures in the young patient on the background of mild COVID-19. These results will help practicing physicians determine management tactics in epilepsy patients. Continuation of this research on the effects of COVID-19 disease and vaccination on the dynamics of epilepsy in a larger cohort is needed.

show abstract

“…While pulmonary and cardiovascular dysfunction usually dominate the acute phase of the illness, many patients experience neurological symptoms (headache, dizziness, fatigue, reduction/loss of smell and taste, myalgia), signs (altered mental status), and unusual/rare disorders (seizures, meningitis, encephalitis, encephalopathy, transverse myelitis, and Guillain-Barre syndrome, among others) [19][20][21][22][23][24][25][26][27][28]. COVID-19 has not increased the incidence of epilepsy but has presented patient management and therapeutic challenges [29,30]. The proportion of patients with COVID-19 reported to have acute new onset neurological disease or symptoms varies significantly depending on the study population, availability of assessment and many other factors; the proportion of these patients in the hospitalized population is also heterogeneous, but in most studies is reported to be 30-60 % [31].…”

mentioning

confidence: 99%

“…ACE2 receptors are present in the human eye [11] where other viruses (Ebola, Marburg or Rubella) can reside after clearance from the systemic circulation [56,57,58]. Measles Virus can develop hypermutated forms in vivo that establish latent neuronal infection which, in the event of subsequent immunosuppression, can reactivate and precipitate the fatal neurological illness Subacute Sclerosing Panencephalitis (SSPE) [59,30]. Persistent or latent brain infection with SARS-CoV-2 is unlikely but has not been ruled out.…”

mentioning

confidence: 99%

COVID-19: neurological sequelae

Spencer¹,

Román²,

Buguet³

et al. 2021

Health Risk Analysis

View full text Add to dashboard Cite

COVID-19, the human primarily respiratory disease caused by the coronavirus SARS-CoV-2, commonly involves the nervous system, the effects of which may persist for many months. Post-acute sequelae of COVID-19 include relapsing and remitting neurological and neuropsychiatric symptoms that can affect children and adults, including those who had mild acute illness. Since longer-term adverse effects on the central and peripheral nervous system of COVID-19 cannot be excluded, patient and societal health trends should be monitored going forward. Urgent present needs include not only global immunization against SARS-CoV-2 but also the reestablishment of lapsed mass vaccination programs to prevent resurgence of other viral diseases (e.g., measles, polio) that can impact the nervous system.

show abstract

Epilepsy and COVID-19: patient management and optimization of antiepileptic therapy during pandemic

Cited by 8 publications

References 22 publications

Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments

Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments

Effects of COVID-19 on the Course of Epilepsy

COVID-19: neurological sequelae

Contact Info

Product

Resources

About